Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Btk inhibitor
AVL-292 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| AVL-292 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AVL-292 | DRUG | 125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops |
Inclusion Criteria: * Women and men ≥18 years of age * Body weight ≥50 kg. * Confirmed diagnosis of B cellNon-Hodgkin Lymphoma(according to World Health Organization \[WHO\] classification)including Chronic Lymphocytic Leukemia/Small cell Lymphocytic Leukemia (International Workshop),or Waldenstrom...
AVL-292 is an investigational small molecule being studied for B cell non-Hodgkin's lymphoma, a type of blood cancer. It was evaluated in a Phase 1 trial that also enrolled patients with chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia, reflecting a broader interest in B cell malignancies.
AVL-292 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound in patients with relapsed or refractory B cell cancers.
AVL-292 is in Phase 1 clinical development. It has completed one Phase 1 dose-escalation trial in patients with relapsed or refractory B cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. It is investigational and has not been approved by the FDA.
AVL-292 has been studied in one completed Phase 1 trial, NCT01351935, titled an escalating dose study in subjects with relapsed or refractory B cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. The trial enrolled 113 patients in the United States and has completed.
The AVL-292 Phase 1 trial, NCT01351935, was an uncontrolled, open-label dose-escalation study, not randomized and not double blinded. It enrolled 113 adults aged 18 and older of any sex with relapsed or refractory B cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, or Waldenstrom's macroglobulinemia, and it has completed.